Updated and revised nomenclature for description of early pregnancy events

Farquharson, Roy G.; Jauniaux, Eric; Exalto, N.

doi:10.1093/humrep/dei167

Cited by 199 publications

(104 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Criteria for the diagnosis of EPL were as follows: (a) the absence of an embryo with a heartbeat ≥2 weeks after a scan that showed a gestational sac without a yolk sac; (b) a nonviable embryonic pregnancy confirmed on the first scan in which the embryonic pole length was ≥7 mm; or if the embryonic pole length was <7 mm on the first scan and nonviability was confirmed based on reproducible evidence of the absence of fetal heart activity; or if the embryonic pole failed to lengthen over 1 week; and (c) an embryonic pregnancy that was viable at the initial scan but had no observable fetal heart activity at the 12th week [20].…”

Section: Ultrasound Measurementsmentioning

confidence: 99%

Correlation analysis between ultrasound findings and abnormal karyotypes in the embryos from early pregnancy loss after in vitro fertilization-embryo transfer

Ouyang

et al. 2016

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The purpose of the study is to evaluate the correlation between ultrasound findings and abnormal karyotypes in early pregnancy losses (EPLs) after in vitro fertilizationembryo transfer (IVF-ET). Methods This retrospective analysis assessed 2172 cases of EPL after IVF-ET occurring between January 2008 and December 2013. The cases were examined via transvaginal ultrasonography (TVS). Embryonic tissue karyotyping following miscarriage was performed using a comparative genomic hybridization (CGH) analysis with fluorescence in situ hybridization (FISH). The correlations between the ultrasound findings and the karyotypes were evaluated. Results Six categories of ultrasound findings were observed: normal ultrasound, empty sac, yolk sac only, small gestational sac, small embryonic pole, and early symmetrical arrested growth. The overall rate of abnormal karyotypes was 44.9 % (976/2172), and the rate of abnormal karyotypes associated with a normal ultrasound, empty sac, yolk sac only, small gestational sac, small embryonic pole, and early symmetrical arrested growth was 49.5 % (218/440), 28.1 % (138/491), 43.4 % (197/454), 50.0 % (43/86), 49.8 % (155/311), and 57.7 % (225/390), respectively. Compared with the other groups, the prevalence of chromosomal abnormalities was significantly higher in the early symmetrical arrested growth group but was markedly lower in the empty sac group in all cases and when cases of 46,XX were excluded (p < 0.05). Trisomy 16 was the most common chromosomal abnormality in the yolk sac only, small embryonic pole and early symmetrical arrested growth groups. In the empty sac, small gestational sac and normal ultrasound groups, monosomy X was the most frequent abnormality. Conclusions Chromosomal anomalies may be associated with specific types of ultrasound findings in EPLs after IVF-ET.

show abstract

Section: Ultrasound Measurementsmentioning

confidence: 99%

Correlation analysis between ultrasound findings and abnormal karyotypes in the embryos from early pregnancy loss after in vitro fertilization-embryo transfer

Ouyang

et al. 2016

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…The outcomes were defined according to the terminology provided by the ICMART (International Committee Monitoring Assisted Reproductive Technologies) glossary [44] and the updated and revised nomenclature for the description of early pregnancy events [14].…”

Section: Outcome Measuresmentioning

confidence: 99%

Coenzyme Q10 and male infertility: a meta-analysis

Lafuente

González-Comadran

Solà

et al. 2013

J Assist Reprod Genet

139

View full text Add to dashboard Cite

Objective To evaluate the effect of coenzyme Q10 treatments in male infertility, specifically in these parameters: live birth and pregnancy rates, CoQ10 seminal concentration, sperm concentration, and sperm motility. Materials and methods Systematic review and meta-analysis in male infertility patients with CoQ10 oral treatments. Three trials were included: 149 males in CoQ10 group and 147 males in placebo group. Results None of the included trials provided any data regarding live births. The results of this meta-analysis show that supplementing infertile men with CoQ10 does not increase pregnancy rates. The analysis showed, among patients receiving CoQ10 treatment, a statistically significant increase in: CoQ10 seminal concentration (RR 49.55, 95 % CI 46.44 to 52.66, I 2 =17 %), sperm concentration (RR 5.33, 95 % CI 4.18 to 6.47, I 2 =58 %), and sperm motility (RR 4.50, 95 % CI 3.92 to 5.08, I 2 =0 %)Conclusion There is no evidence in the literature that CoQ10 increases either live birth or pregnancy rates, but there is a global improvement in sperm parameters. Adequately powered, robust trials of individual and combination antioxidant therapies are required to guide clinical practice.

show abstract

“…Therefore, the traditional grouping of all pregnancy losses before 20 weeks has been revised. 5 Standard investigations fail to reveal any apparent cause in .50% of the women. 1,2 On the basis of a parallel drawn with the antiphospholipid syndrome, hypotheses on thrombotic mechanisms were raised in unexplained pregnancy loss.…”

Section: Introductionmentioning

confidence: 99%

Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial

Pasquier

Martin

Bohec

et al. 2015

Blood

104

102

View full text Add to dashboard Cite

Key Points• The use of low-molecularweight heparin did not improve live-birth rates in nonthrombophilic women with consecutive recurrent miscarriage.• Prophylactic doses of lowmolecular-weight heparin should no longer be prescribed in this clinical setting.It is common practice in many centers to offer antithrombotic medications to women with unexplained recurrent miscarriage, in the presence or absence of inherited thrombophilia. Although no benefit of aspirin vs placebo has been clearly demonstrated, a doubleblind placebo-controlled trial on the effect of low-molecular-weight heparin is lacking. We enrolled 258 pregnant women with a history of unexplained recurrent miscarriage ( ‡2 consecutive miscarriages before 15 weeks' gestation) and a negative thrombophilia workup. They were randomly assigned to receive one daily subcutaneous injection of enoxaparin 40 mg or placebo until 35 weeks' gestation. We included 256 women (mean age 32 years, ‡3 miscarriages: 72%; mean gestational age 39 days of amenorrhea) in the intention-to-treat analysis; 66.6% of 138 who received enoxaparin had a live birth vs 72.9% of 118 who received placebo. The absolute difference was 26% (95% CI, 217.1 to 5.1), excluding a 10% increase in the rate of live-birth on enoxaparin (P 5 .34). In this first randomized, double-blind, placebo-controlled trial, enoxaparin (40 mg once daily) did not improve the chance of a live birth in nonthrombophilic women with unexplained recurrent miscarriage. This trial is registered at www.ClinicalTrials.gov as #NCT00740545 and the French

show abstract

Updated and revised nomenclature for description of early pregnancy events

Cited by 199 publications

References 15 publications

Correlation analysis between ultrasound findings and abnormal karyotypes in the embryos from early pregnancy loss after in vitro fertilization-embryo transfer

Correlation analysis between ultrasound findings and abnormal karyotypes in the embryos from early pregnancy loss after in vitro fertilization-embryo transfer

Coenzyme Q10 and male infertility: a meta-analysis

Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial

Contact Info

Product

Resources

About